| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Karin Wuertz | Q44449036 |
| Olga Krupkova | Q63976483 | ||
| P2093 | author name string | Lenka Besse | |
| Andrej Besse | |||
| Robert Bowles | |||
| Elena Cambria | |||
| P2860 | cites work | Degeneration of the intervertebral disc | Q21195247 |
| Genome engineering using the CRISPR-Cas9 system | Q22122027 | ||
| CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes | Q24625361 | ||
| A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity | Q24669850 | ||
| Strategies to Enhance the Effectiveness of Adult Stem Cell Therapy for Ischemic Heart Diseases Affecting the Elderly Patients | Q26771298 | ||
| Challenges and strategies in the repair of ruptured annulus fibrosus | Q26829807 | ||
| Role of cytokines in intervertebral disc degeneration: pain and disc content | Q27001658 | ||
| Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation | Q27681624 | ||
| Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA | Q27681727 | ||
| RNA-programmed genome editing in human cells | Q28044562 | ||
| Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV | Q28235281 | ||
| Development and applications of CRISPR-Cas9 for genome engineering | Q28241526 | ||
| RNA-guided gene activation by CRISPR-Cas9-based transcription factors | Q28295458 | ||
| One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering | Q29547524 | ||
| ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering | Q29615505 | ||
| Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression | Q29615784 | ||
| Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity | Q29615792 | ||
| DNA targeting specificity of RNA-guided Cas9 nucleases | Q29615793 | ||
| Genome-scale CRISPR-Cas9 knockout screening in human cells | Q29616044 | ||
| Genetic screens in human cells using the CRISPR-Cas9 system | Q29617411 | ||
| Papain-induced in vitro disc degeneration model for the study of injectable nucleus pulposus therapy | Q30586320 | ||
| CRISPR/Cas9 knockout of HAS2 in rat chondrosarcoma chondrocytes demonstrates the requirement of hyaluronan for aggrecan retention | Q32872051 | ||
| Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR/Cas9-Mediated Gene Editing | Q33655722 | ||
| Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins | Q33657682 | ||
| Rapid generation of mouse models with defined point mutations by the CRISPR/Cas9 system. | Q33788990 | ||
| Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein | Q33900031 | ||
| Intervertebral disc repair using adipose tissue-derived stem and regenerative cells: experiments in a canine model | Q44729247 | ||
| * CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments | Q45863718 | ||
| In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation. | Q46727259 | ||
| Development of an organ culture system for long-term survival of the intact human intervertebral disc. | Q46940338 | ||
| First-In-Human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready? | Q47283164 | ||
| Rare coding variants in MAPK7 predispose to adolescent idiopathic scoliosis | Q47320554 | ||
| RNA editing with CRISPR-Cas13. | Q47410076 | ||
| Genome Engineering for Personalized Arthritis Therapeutics | Q47697061 | ||
| Ethical Issues Regarding CRISPR Mediated Genome Editing | Q47961470 | ||
| Caveolae Protect Notochord Cells against Catastrophic Mechanical Failure during Development. | Q48224827 | ||
| 2009 ISSLS Prize Winner: Does discography cause accelerated progression of degeneration changes in the lumbar disc: a ten-year matched cohort study | Q48313482 | ||
| CRISPR Epigenome Editing of AKAP150 in DRG Neurons Abolishes Degenerative IVD-Induced Neuronal Activation. | Q48732898 | ||
| Global profiling of the gene expression and alternative splicing events during hypoxia-regulated chondrogenic differentiation in human cartilage endplate-derived stem cells. | Q50526762 | ||
| Generation of articular chondrocytes from human pluripotent stem cells. | Q50587550 | ||
| Transplantation of mesenchymal stem cells embedded in Atelocollagen gel to the intervertebral disc: a potential therapeutic model for disc degeneration. | Q51023294 | ||
| CRISPR gene-editing tested in a person for the first time. | Q51047142 | ||
| Science and Bioethics of CRISPR-Cas9 Gene Editing: An Analysis Towards Separating Facts and Fiction. | Q52408012 | ||
| Generation of CRISPR/Cas9-mediated gene-targeted pigs via somatic cell nuclear transfer. | Q52423182 | ||
| Epigallocatechin 3-gallate suppresses interleukin-1β-induced inflammatory responses in intervertebral disc cells in vitro and reduces radiculopathic pain in rats. | Q54307962 | ||
| HIF-1 alpha is a regulator of galectin-3 expression in the intervertebral disc | Q80530258 | ||
| Pharmacological inhibition of tumor necrosis factor may reduce pain behavior changes induced by experimental disc puncture in the rat: an experimental study in rats | Q82244625 | ||
| Efficient isolation of specific genomic regions and identification of associated proteins by engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP) using CRISPR. | Q34037845 | ||
| Genome engineering in cattle: recent technological advancements | Q34042998 | ||
| CASFISH: CRISPR/Cas9-mediated in situ labeling of genomic loci in fixed cells | Q34044790 | ||
| Genome-wide inactivation of porcine endogenous retroviruses (PERVs). | Q34045122 | ||
| Rationally engineered Cas9 nucleases with improved specificity | Q34045530 | ||
| CRISPR/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues | Q34047602 | ||
| TRPV4 agonists and antagonists | Q34192398 | ||
| Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation | Q34443093 | ||
| Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. | Q34463483 | ||
| Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining | Q34468164 | ||
| Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions | Q34475839 | ||
| Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR. | Q34477489 | ||
| Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes. | Q34551100 | ||
| Integrin targeted therapeutics | Q34912684 | ||
| Cost of low back pain in Switzerland in 2005 | Q35178029 | ||
| Efficient gene knockout in goats using CRISPR/Cas9 system | Q35238265 | ||
| Selective Distal Enhancer Control of the Mmp13 Gene Identified through Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) Genomic Deletions | Q35536330 | ||
| Aquaporin 1 and 5 expression decreases during human intervertebral disc degeneration: Novel HIF-1-mediated regulation of aquaporins in NP cells | Q35828477 | ||
| Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. | Q35896845 | ||
| Piperine mediates LPS induced inflammatory and catabolic effects in rat intervertebral disc. | Q35918922 | ||
| Nutrition of the intervertebral disc | Q35963858 | ||
| Expression of fibronectin and TGF-beta1 mRNA and protein suggest altered regulation of extracellular matrix in degenerated disc tissue | Q36333875 | ||
| Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements | Q36338669 | ||
| Rapid reverse genetic screening using CRISPR in zebrafish | Q36341911 | ||
| CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients | Q36512076 | ||
| Genetics of disc degeneration | Q36526935 | ||
| Nerve Growth Factor Is Regulated by Toll-Like Receptor 2 in Human Intervertebral Discs | Q36574021 | ||
| Rho-Associated Kinase Inhibitor Immortalizes Rat Nucleus Pulposus and Annulus Fibrosus Cells: Establishment of Intervertebral Disc Cell Lines With Novel Approaches. | Q36625971 | ||
| Are animal models useful for studying human disc disorders/degeneration? | Q36627417 | ||
| 2002 SSE Award Competition in Basic Science: expression of major matrix metalloproteinases is associated with intervertebral disc degradation and resorption | Q36723561 | ||
| Systematic quantification of HDR and NHEJ reveals effects of locus, nuclease, and cell type on genome-editing | Q36748165 | ||
| Rosa26-targeted sheep gene knock-in via CRISPR-Cas9 system | Q36785065 | ||
| Genetic polymorphisms associated with intervertebral disc degeneration. | Q36848898 | ||
| Lumbar degenerative disk disease. | Q36947907 | ||
| N-cadherin is Key to Expression of the Nucleus Pulposus Cell Phenotype under Selective Substrate Culture Conditions | Q36996310 | ||
| Generation of Genetically Modified Mice Using the CRISPR-Cas9 Genome-Editing System | Q36998538 | ||
| Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation. | Q37086614 | ||
| The CRISPR/Cas9 system for gene editing and its potential application in pain research | Q37148023 | ||
| Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9. | Q37223664 | ||
| Focused screening of mitochondrial metabolism reveals a crucial role for a tumor suppressor Hbp1 in ovarian reserve. | Q37294292 | ||
| Reduced tissue osmolarity increases TRPV4 expression and pro-inflammatory cytokines in intervertebral disc cells. | Q37354510 | ||
| Inflammatory mediators in intervertebral disk degeneration and discogenic pain | Q37371897 | ||
| In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration | Q37673657 | ||
| Degeneration and regeneration of the intervertebral disc: lessons from development | Q37814771 | ||
| Intervertebral disc regeneration: from the degenerative cascade to molecular therapy and tissue engineering | Q38091404 | ||
| Intervertebral disc regeneration: do nutrients lead the way? | Q38219054 | ||
| Advancing the cellular and molecular therapy for intervertebral disc disease | Q38226106 | ||
| Delivery systems for the treatment of degenerated intervertebral discs | Q38275812 | ||
| Stem cell therapy for intervertebral disc regeneration: obstacles and solutions | Q38364573 | ||
| Biologic response of human intervertebral disc cells to gene therapy cocktail. | Q38499923 | ||
| Delivery and Specificity of CRISPR-Cas9 Genome Editing Technologies for Human Gene Therapy. | Q38525774 | ||
| miR-322 stabilizes MEK1 expression to inhibit RAF/MEK/ERK pathway activation in cartilage. | Q38603219 | ||
| Inflammatory mediators and signalling pathways controlling intervertebral disc degeneration. | Q38795030 | ||
| CRISPR/Cas9 in Genome Editing and Beyond | Q38825624 | ||
| CRISPR/Cas9 mediated generation of stable chondrocyte cell lines with targeted gene knockouts; analysis of an aggrecan knockout cell line | Q38952939 | ||
| Factors involved in the nutrition of the human lumbar intervertebral disc: cellularity and diffusion of glucose in vitro | Q39223995 | ||
| The CRISPR/Cas9 system: Their delivery, in vivo and ex vivo applications and clinical development by startups | Q39260698 | ||
| Human anulus fibrosis and nucleus pulposus cells of the intervertebral disc: effect of degeneration and culture system on cell phenotype | Q40363306 | ||
| Kinesin-1 promotes chondrocyte maintenance during skeletal morphogenesis. | Q41186437 | ||
| An Inflammatory Nucleus Pulposus Tissue Culture Model to Test Molecular Regenerative Therapies: Validation with Epigallocatechin 3-Gallate | Q41613329 | ||
| Treatment of rabbit intervertebral disc degeneration with co-transfection by adeno-associated virus-mediated SOX9 and osteogenic protein-1 double genes in vivo | Q42268715 | ||
| Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs | Q42278257 | ||
| Human intervertebral disc internal strain in compression: the effect of disc region, loading position, and degeneration | Q42321313 | ||
| Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent | Q42377052 | ||
| Integrin-mediated interactions with extracellular matrix proteins for nucleus pulposus cells of the human intervertebral disc | Q42909500 | ||
| Fibronectin splicing variants in human intervertebral disc and association with disc degeneration | Q42971265 | ||
| Generation of gene-target dogs using CRISPR/Cas9 system | Q43472142 | ||
| Annular tears and disc degeneration in the lumbar spine. A post-mortem study of 135 discs | Q43493110 | ||
| The red wine polyphenol resveratrol shows promising potential for the treatment of nucleus pulposus-mediated pain in vitro and in vivo | Q44448974 | ||
| P433 | issue | 1 | |
| P921 | main subject | Cas9 | Q16965677 |
| CRISPR | Q412563 | ||
| pathology | Q7208 | ||
| CRISPR-Cas method | Q17310682 | ||
| P304 | page(s) | e1003 | |
| P577 | publication date | 2018-03-15 | |
| P1433 | published in | JOR Spine | Q73541371 |
| P1476 | title | The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies | |
| P478 | volume | 1 |
Search more.